Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Eur J Pharmacol ; 401(3): 419-28, 2000 Aug 11.
Article in English | MEDLINE | ID: mdl-10936502

ABSTRACT

For progression to clinical trials in stroke, putative neuroprotective compounds should show robust efficacy post-ischaemia in several experimental models of stroke. This paper describes the characterisation of (+)(1S, 2R)-cis-1-[4-(1-methyl-1-phenylethyl)phenoxy]-2-methylamino indane hydrochloride (SB-221420-A), a Ca(2+) and Na(+) channel antagonist. SB-221420-A inhibited (IC(50)=2.2 microM) N-type voltage-operated Ca(2+) channel currents in cultured superior cervical ganglion neurons, which were pretreated with 10 microM nimodipine to block L-type voltage-operated Ca(2+) channel currents. In dorsal root ganglion neurons pretreated with 1 microM omega-conotoxin GVIA to block N-type voltage-operated Ca(2+) channel currents, SB-221420-A inhibited the residual Ca(2+) current with an IC(50) of 7 microM. SB-221420-A also inhibited Na(+) currents in dorsal root ganglion neurons with an IC(50) of 8 microM. In rats, the pharmacokinetic profile of SB-221420-A shows that it has a half-life of 6.4 h, a high volume of distribution, is highly brain penetrating, and has no persistent metabolites. Following bilateral carotid artery occlusion in gerbils, SB-221420-A significantly reduced the level of ischaemia-induced hyperlocomotor activity and the extent of hippocampal CA1 cell loss compared to the ischaemic vehicle-treated group. SB-221420-A was also effective in focal models of ischaemia. In the mouse permanent middle cerebral artery occlusion model, SB-221420-A (10 mg/kg) administered intravenously, post-ischaemia significantly (P<0.05) reduced lesion volume compared to the ischaemic vehicle-treated group. In the normotensive rat permanent middle cerebral artery occlusion model, SB-221420-A (10 mg/kg) administered intravenously over 1 h, beginning 30 min postmiddle cerebral artery occlusion, significantly (P<0.05) reduced lesion volume from 291+/-16 to 153+/-30 mm(3), compared to ischaemic vehicle-treated controls when measured 24 h postmiddle cerebral artery occlusion. Efficacy was maintained when the same total dose of SB-221420-A was infused over a 6-h period, beginning 30 min postmiddle cerebral artery occlusion. SB-221420-A also significantly (P<0.05) reduced lesion volume following transient middle cerebral artery occlusion in normotensive rats and permanent middle cerebral artery occlusion in spontaneously hypertensive rats (SHR). Investigation of the side effect profile using the Irwin screen in mice revealed that, at neuroprotective doses, there were no overt behavioural or cardiovascular changes. These data demonstrate that robust neuroprotection can be seen post-ischaemia with SB-221420-A in both global and focal ischaemia with no adverse effects at neuroprotective doses, and indicate the potential utility of a mixed cation blocker to improve outcome in cerebral ischaemia.


Subject(s)
Calcium Channel Blockers/pharmacology , Indans/pharmacology , Neuroprotective Agents/pharmacology , Sodium Channel Blockers , Stroke/prevention & control , Anesthesia , Animals , Animals, Newborn , Brain/drug effects , Brain/pathology , Carotid Stenosis/physiopathology , Carotid Stenosis/prevention & control , Cells, Cultured , Consciousness , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Gerbillinae , Hemodynamics/drug effects , Hypertension/physiopathology , Indans/pharmacokinetics , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/prevention & control , Ischemic Attack, Transient/physiopathology , Ischemic Attack, Transient/prevention & control , Male , Membrane Potentials/drug effects , Metabolic Clearance Rate , Mice , Motor Activity/drug effects , Neurons, Afferent/cytology , Neurons, Afferent/drug effects , Neurons, Afferent/physiology , Rats , Rats, Inbred SHR , Rats, Sprague-Dawley , Stroke/physiopathology , Tissue Distribution
2.
Gastroenterology ; 101(1): 55-65, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1646142

ABSTRACT

An investigation of the mechanism of peppermint oil action was performed using isolated pharmacological preparations from guinea pig large intestine and patch clamp electrophysiology techniques on rabbit jejunum. Peppermint oil relaxed carbachol-contracted guinea pig taenia coli (IC50, 22.1 micrograms/mL) and inhibited spontaneous activity in the guinea pig colon (IC50, 25.9 micrograms/mL) and rabbit jejunum (IC50, 15.2 micrograms/mL). Peppermint oil markedly attenuated contractile responses in the guinea pig taenia coli to acetylcholine, histamine, 5-hydroxytryptamine, and substance P. Peppermint oil reduced contractions evoked by potassium depolarization and calcium contractions evoked in depolarizing Krebs solutions in taenia coli. Potential-dependent calcium currents recorded using the whole cell clamp configuration in rabbit jejunum smooth muscle cells were inhibited by peppermint oil in a concentration-dependent manner. Peppermint oil both reduced peak current amplitude and increased the rate of current decay. The effect of peppermint oil resembled that of the dihydropyridine calcium antagonists. It is concluded that peppermint oil relaxes gastrointestinal smooth muscle by reducing calcium influx.


Subject(s)
Calcium Channels/drug effects , Digestive System/drug effects , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Oils, Volatile/pharmacology , Plant Oils/pharmacology , Animals , Colon/drug effects , Colon/physiology , Digestive System Physiological Phenomena , Electrophysiology , Guinea Pigs , In Vitro Techniques , Jejunum/drug effects , Jejunum/physiology , Male , Mentha piperita , Muscle, Smooth/physiology , Rabbits
3.
Clin Prev Dent ; 6(4): 13-9, 1984.
Article in English | MEDLINE | ID: mdl-6331953
SELECTION OF CITATIONS
SEARCH DETAIL